<DOC>
	<DOCNO>NCT01228331</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving drug ( combination chemotherapy ) may kill cancer cell . Radiation therapy use high-energy x-ray kill cancer cell . It yet know whether give clofarabine high-dose cytarabine , pegaspargase , combination chemotherapy follow daunorubicin hydrochloride doxorubicin hydrochloride effective treat young patient acute lymphoblastic leukemia . PURPOSE : This randomized phase II/III trial study side effect give clofarabine compare give high-dose cytarabine , pegaspargase , combination chemotherapy follow daunorubicin hydrochloride doxorubicin hydrochloride see well work treat young patient T-cell acute lymphoblastic leukemia precursor B-cell acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Clofarabine High-Dose Cytarabine Pegaspargase Children With ALL</brief_title>
	<detailed_description>OBJECTIVES : Primary - To investigate safety efficacy clofarabine combine pegaspargase patient high-risk acute lymphoblastic leukemia first phase study . ( Phase II ) - To investigate , term minimal-residual disease ( MRD ) , cytotoxic efficacy clofarabine compare high-dose cytarabine combination pegaspargase patient . ( Phase III ) - To compare incidence infectious complication administration daunorubicin hydrochloride versus doxorubicin hydrochloride reinduction . Secondary - To compare safety profile clofarabine pegaspargase versus high-dose cytarabine pegaspargase patient . - To compare , term MRD , efficacy clofarabine pegaspargase high-dose cytarabine pegaspargase , respectively , versus methotrexate , cyclophosphamide , asparaginase study GER-COALL-07-03 , historical control group ( retrospective comparison ) . - To determine influence MRD-based stratification COALL-09 overall survival event-free survival historical comparison previous COALL study . OUTLINE : This multicenter , sequential phase II/III study . Patients stratify low risk ( LR ) high risk ( HR ) depend peripheral white blood cell count diagnosis , age diagnosis , immunological subtype . Patients undergo 2 randomization ( 1 intensification 1 reinduction ) study . - Preliminary treatment : All patient receive daunorubicin hydrochloride IV 24 hour day -7 methotrexate intrathecally ( IT ) day -9 , -8 , -7 . - Induction : All patient receive vincristine IV day 1 , 8 , 15 , 22 ; daunorubicin hydrochloride IV 24 hour day 1 , 8 , 15 ; oral prednisone 3-4 time daily day 1-28 . Patients assess minimal-residual disease ( MRD ) status induction phase . Patients remission day 29 treat study . Patients LR disease stratify LR-reduced ( LR-R ) , LR-standard ( LR-S ) , LR-intensified ( LR-I ) group ; patient HR disease stratify HR-reduced ( HR-R ) , HR-standard ( HR-S ) , HR-intensified ( HR-I ) group . Patients LR-R HR-R group undergo randomization study . - Intensification ( randomization 1 ) : Patients receive therapy accord risk disease subtypes . Some patient different risk group randomized* receive high-dose ( HD ) cytarabine pegaspargase clofarabine pegaspargase . - LR-R LR-S : Patients receive medium-high-dose ( mHD ) methotrexate IV 24 hour day 50 , 64 , 78 ; etoposide phosphate IV 1-2 hour cytarabine IV 1 hour day 66 ; oral mercaptopurine day 50-56 78-120 ; oral thioguanine day 64-70 ; methotrexate IT day 29 , 50 , 64 , 78 . Patients LR-S group still detectable MRD load day 29 randomize ( randomization 1 ) 1 2 arm receive cytarabine pegaspargase vs. clofarabine pegaspargase . - Arm I ( cytarabine pegaspargase ) Patients receive HD cytarabine IV 3 hour twice daily day 29-31 pegaspargase IV 2 hour day 31 , 52 , 80 . - Arm II ( clofarabine pegaspargase ) Patients receive clofarabine IV 2 hour day 29-33 pegaspargase IV 2 hour day 33 , 52 , 80 . - LR-I precursor B-cell acute lymphoblastic leukemia ( ALL ) HR-S HR-I : Patients receive cyclophosphamide IV 30 minute day 50 64 ; mHD IV 24 hour day 51 , 65 , 78 , 92 ; etoposide phosphate IV 1-2 hour cytarabine IV 1 hour day 80 94 ; oral mercaptopurine day 64-70 92-98 ; oral thioguanine day 78-84 ; methotrexate IT day 29 , 51 , 65 , 78 , 92 . All precursor B-cell ALL patient detectable MRD load day 29 T-cell ALL patient MRD load ≥ 10³ day 29 randomized* ( randomization 1 ) 1 2 arm receive cytarabine pegaspargase vs. clofarabine pegaspargase . - Arm I ( cytarabine pegaspargase ) Patients receive HD cytarabine IV 3 hour twice daily day 29-31 106-108 pegaspargase IV 2 hour day 31 , 53 , 67 , 108 . - Arm II ( clofarabine pegaspargase ) Patients receive clofarabine* IV 2 hour day 29-33 pegaspargase IV 2 hour day 33 , 53 , 67 , 108 . - NOTE : *In phase II , patient MRD load ≥ 104 ( day 29 ) receive clofarabine pegaspargase without randomization . - T-cell ALL HR ( HR-R , HR-S , HR-I ) : Patients receive cyclophosphamide IV 30 minute day 29 64 ; mHD methotrexate IV 24 hour day 30 , 65 , 78 , 92 ; etoposide phosphate IV 1-2 hour cytarabine IV 1 hour day 80 94 ; oral mercaptopurine day 64-70 92-98 ; oral thioguanine day 78-84 ; methotrexate IT day 30 , 43 , 65 , 78 , 92 . Patients HR-S HR-I group randomized* ( randomization 1 ) 1 2 arm receive cytarabine pegaspargase vs. clofarabine pegaspargase . - Arm I ( cytarabine pegaspargase ) : Patients receive HD cytarabine IV 3 hour twice daily day 43-45 106-108 pegaspargase IV 2 hour day 32 , 45 , 67 , 108 . - Arm II ( clofarabine pegaspargase ) : Patients receive clofarabine IV 2 hour day 43-47 pegaspargase IV 2 hour day 32 , 47 , 67 , 108 . Patients HR-I group also receive amsacrine IV 4 hour etoposide phosphate IV 2 hour day 127 128 , methylprednisolone IV 30 minute day 127-130 , methotrexate IT day 127 , end intensification . NOTE : *In phase II , patient MRD load ≥ 103 ( day 43 ) receive clofarabine pegaspargase without randomization . - CNS therapy : All patient initial CNS involvement undergo cranial radiotherapy total 12 18 Gy . HR patient ( precursor B-cell ALL initial WBC count ≥ 200/nL T-cell ALL initial WBC count ≥ 100/nL ) initial CNS involvement also undergo cranial radiotherapy total 12 Gy , begin 2-3 week last dose HD cytarabine clofarabine . LR patient HR patient ( precursor B-cell ALL initial WBC count &lt; 200/nL T-cell ALL initial WBC count &lt; 100/nL ) initial CNS involvement receive initial cranial radiotherapy . At begin CNS therapy , cranial radiotherapy , HR-I patient receive vincristine IV day 1 ; doxorubicin hydrochloride IV 24 hour day 1 ; oral dexamethasone 3 time daily day 1-7 ; pegaspargase IV 2 hour day 7 . All patient receive interim therapy comprise 3 dos ( 2 week 1 1 week 3 ) methotrexate IT oral mercaptopurine daily 4 week intensification reinduction . - Reinduction ( randomization 2 ) : Patients undergo reinduction immediately completion interim therapy . Patients LR-S , LR-I , HR-S , HR-I group randomize 1 2 arm ( doxorubicin hydrochloride vs. daunorubicin hydrochloride ) - LR-S : Patients receive vincristine IV day 1 8 , oral dexamethasone day 1-14 , pegaspargase IV 2 hour day 9 , cyclophosphamide IV 30 minute day 22 , cytarabine IV intramuscularly ( IM ) day 23-26 , oral thioguanine day 22-28 , methotrexate IT day 1 , 22 , 36 . - Arm III ( doxorubicin hydrochloride ) Patients receive doxorubicin hydrochloride IV 24 hour day 1 8 . - Arm IV ( daunorubicin hydrochloride ) : Patients receive daunorubicin hydrochloride IV 24 hour day 1 8 . - LR-R HR-R : Patients randomize . They receive vincristine IV day 1 8 , oral dexamethasone day 1-14 , pegaspargase IV 2 hour day 8 , methotrexate IT day 1 15 . - LR-I , HR-S , HR-I : Patients receive vincristine IV day 1 , 8 , 22 , 29 ; oral dexamethasone twice daily day 1-14 22-35 ; cyclophosphamide IV 30 minute day 43 57 ; cytarabine IV IM day 43-46 57-60 ; oral thioguanine day 43-49 57-63 ; methotrexate IT* day 1 , 22 , 43 . - Arm III ( doxorubicin hydrochloride ) Patients receive doxorubicin hydrochloride IV 24 hour day 1 , 8 , 22 , 29 . - Arm IV ( daunorubicin hydrochloride ) Patients receive daunorubicin hydrochloride IV 24 hour day 1 , 8 , 22 , 29 . NOTE : *Patients underwent cranial radiotherapy receive methotrexate IT . - Maintenance : Beginning 2-3 week reinduction , patient receive oral mercaptopurine daily oral methotrexate weekly 2 year . Except LR-R HR-R , patient also receive pegaspargase IV 2 hour every 3 week 3 dos . Patients undergone CNS radiotherapy receive methotrexate IT 3 , 6 , 9 month . Blood bone marrow sample may collect periodically research study . After completion study treatment , patient follow monthly 1 year , every 3 month 2 year , every 6 month 2 year , annually 5 year . PROJECTED ACCRUAL : A total 41 high-risk patient accrue phase II , 296 patient first randomization ( phase III ) , 396 patient second randomization accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Amsacrine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : diagnosis first 18th birthday AND confirm diagnosis acute Bprecursor Tcell leukemia AND parent guardians/patients give consent inclusion study transmission data AND none exclusion criterion accomplish Exclusion criterion : BCR/ABL rearrangement positive OR prior cytostatic treatment last &gt; 7 day prior treatment cytostatic drug vincristine , daunorubicin prednisone OR prior severe illness make treatment per protocol impossible outset ( BUT trisomy 21 exclusion criterion ) OR absence baseline data require assignment risk group accordance protocol ( BUT patient MRD value could determine technical reason treat protocol patient ) OR disease secondary malignancy relapse OR death start treatment</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>